Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number

被引：0
作者：
B. Wirth
L. Brichta
B. Schrank
H. Lochmüller
S. Blick
A. Baasner
R. Heller
机构：
[1] University of Cologne,Institute of Human Genetics
[2] University of Cologne,Institute of Genetics
[3] University of Cologne,Center for Molecular Medicine Cologne
[4] Stiftung Deutsche Klinik für Diagnostik,Department of Neurology
[5] Friedrich-Baur-Institut,undefined
来源：
Human Genetics | 2006年 / 119卷
关键词：
Spinal muscular atrophy (SMA); Survival motor neuron (SMN); Quantification of SMN2; Natural history;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Spinal muscular atrophy (SMA) is a recessive neuromuscular disorder caused by loss of the SMN1 gene. The clinical distinction between SMA type I to IV reflects different age of onset and disease severity. SMN2, a nearly identical copy gene of SMN1, produces only 10% of full-length SMN RNA/protein and is an excellent target for a potential therapy. Several clinical trials with drugs that increase the SMN2 expression such as valproic acid and phenylbutyrate are in progress. Solid natural history data for SMA are crucial to enable a correlation between genotype and phenotype as well as the outcome of therapy. We provide genotypic and phenotypic data from 115 SMA patients with type IIIa (age of onset <3 years), type IIIb (age of onset >3 years) and rare type IV (onset >30 years). While 62% of type IIIa patients carry two or three SMN2 copies, 65% of type IIIb patients carry four or five SMN2 copies. Three type IV SMA patients had four and one had six SMN2 copies. Our data support the disease-modifying role of SMN2 leading to later onset and a better prognosis. A statistically significant correlation for ≥4 SMN2 copies with SMA type IIIb or a milder phenotype suggests that SMN2 copy number can be used as a clinical prognostic indicator in SMA patients. The additional case of a foetus with homozygous SMN1 deletion and postnatal measurement of five SMN2 copies illustrates the role of genotypic information in making informed decisions on the management and therapy of such patients.
引用
收藏
页码：422 / 428
页数：6
相关论文
共 240 条
[1]  
Andreassi C(2004)Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy Eur J Hum Genet 12 59-65
[2]  
Angelozzi C(1993)Presymptomatic diagnosis of SMA III by genotype analysis Am J Med Genet 45 408-411
[3]  
Tiziano FD(1995)Genetic homogeneity between childhood-onset and adult-onset autosomal recessive spinal muscular atrophy Lancet 346 741-742
[4]  
Vitali T(2005)Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients Eur J Hum Genet 13 256-259
[5]  
De Vincenzi E(2003)Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy Hum Mol Genet 12 2481-2489
[6]  
Boninsegna A(2004)Pilot study of in-vivo effects of valproic acid on SMN gene expression in SMA carriers Eur J Hum Genet 1 5-15
[7]  
Villanova M(1997)When is a deletion not a deletion? When it is converted Am J Hum Genet 61 9-1713
[8]  
Bertini E(1995)SMN gene deletions in adult-onset spinal muscular atrophy Lancet 346 1712-808
[9]  
Pini A(1995)Deletions of the survival motor neuron gene in unaffected siblings of patients with spinal muscular atrophy Am J Hum Genet 57 805-237
[10]  
Neri G(2003)Prevalence of SMN1 deletion and duplication in carrier and normal populations: implication for genetic counselling J Med Genet 40 E39-368
12345678910